{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=31", "query": { "condition": "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 930, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T00:23:13.421Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06561685", "title": "A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor", "Advanced Solid Tumor", "Non-small Cell Lung Cancer", "SMARCA4-Deficient Tumor" ], "interventions": [ { "name": "LY4050784", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2024-09-19", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 17, "location_summary": "Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561685" }, { "nct_id": "NCT03679767", "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer", "Locally Advanced Urothelial Cancer", "Metastatic Urothelial Cancer", "Unresectable Melanoma", "Metastatic Melanoma", "Locally Advanced Renal Cell Carcinoma", "Metastatic Clear-Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2019-01-09", "completion_date": "2022-06-28", "has_results": true, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 18, "location_summary": "Fresno, California • San Marcos, California • Santa Rosa, California + 13 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03679767" }, { "nct_id": "NCT06784193", "title": "Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)", "Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Metastatic Breast Cancer", "Fulvestrant", "Palazestrant" ], "interventions": [ { "name": "OP-3136", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palazestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2024-12-16", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 13, "location_summary": "Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06784193" }, { "nct_id": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "PLN-101095", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pliant Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2023-08-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 16, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 11 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270706" }, { "nct_id": "NCT00373204", "title": "Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Motexafin Gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2006-05", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 7, "location_summary": "La Verne, California • Rochester, New York • Canton, Ohio + 4 more", "locations": [ { "city": "La Verne", "state": "California" }, { "city": "Rochester", "state": "New York" }, { "city": "Canton", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00373204" }, { "nct_id": "NCT04751747", "title": "Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Locally Advanced Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Contrast Agent", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-02-11", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04751747" }, { "nct_id": "NCT07458347", "title": "A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KRAS-mutant Non-small Cell Lung Cancer (NSCLC)", "KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)", "KRAS-mutant Colorectal Cancer (CRC)", "Other KRAS-mutant Solid Tumors" ], "interventions": [ { "name": "KST-6051", "type": "DRUG" }, { "name": "Gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kestrel Therapeutics, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 545, "start_date": "2026-04-21", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 9, "location_summary": "Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07458347" }, { "nct_id": "NCT07155187", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "c-MET" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 490, "start_date": "2025-12-10", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 16, "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 13 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07155187" }, { "nct_id": "NCT03149549", "title": "PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Breast Cancer", "Non Small Cell Lung Cancer", "Head and Neck Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CX-2009", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2017-06-01", "completion_date": "2020-09-10", "has_results": true, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 16, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03149549" }, { "nct_id": "NCT00738387", "title": "A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "ASA404", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2008-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-24", "last_synced_at": "2026-10-16T00:23:13.421Z", "location_count": 88, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738387" } ] }